Safety and efficacy of combined use of venetoclax and pirtobrutinib

Venetoclax (Venetoclax) and Pirtobrutinib (Pirtobrutinib) have attracted much attention in the treatment of hematological tumors in recent years. The two targeted drugs respectively target different signaling pathways and play a key role in diseases such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL). As research continues to deepen, the combined use of these two drugs has become a new strategy for treating drug-resistant or high-risk patients. So what is the safety and efficacy of combining venetoclax with pitobrutinib? The following will conduct a detailed analysis from four aspects: mechanism, clinical effect, safety and future prospects.

1. Complementary mechanisms of action, targeted synergy to enhance efficacy

Veneclar is a selectiveBCL-2 inhibitor that works primarily by inducing apoptosis in tumor cells. BCL-2 is an anti-apoptotic protein that is often abnormally highly expressed in hematological malignancies such as CLL, causing tumor cells to escape death. By targeting BCL-2, venetoclax effectively breaks this "protective umbrella" and promotes natural apoptosis of tumor cells.

Pirtobrutinib (Pirtobrutinib) is a new generation of non-covalent BTK inhibitors. It is different from the first-generation covalent BTK inhibitors such as ibrutinib. It can It effectively acts on wild-type and mutant BTK, including common drug-resistant mutations such as C481S, so it shows better efficacy in patients who have previously received BTK inhibitors but developed resistance or side effects. Pitobrutinib interferes with the survival and expansion of tumor cells by blocking the B cell receptor (BCR) signaling pathway.

The theoretical basis for the combined use of the two is: BTK and BCL-2 are in different signaling pathways for lymphocyte survival. The combined use can achieve a more effective "double-click attack" on tumor cells, increase cell death rate, and reduce the occurrence of drug resistance.

2. Clinical trials have initially shown results, and positive curative effects are expected.

In clinical practice, combination therapy with venetoclax and first-generation BTK inhibitors has achieved significant efficacy, such as ibrutinib+venetoclax combination is widely used in initial treatment or relapsed / refractory treatmentCLL. With the emergence of pitobrutinib, its combination with venetoclax has quickly entered the clinical research stage.

In the early clinical data released in 2022 and 2023, a study on pitobrutinib combined with venetex Studies of clar ± obinutuzumab in patients with relapsed/refractory CLL have shown encouraging results with this combination treatment. Most patients achieved deep remission in a short period of time, and some patients achieved minimal residual disease (MRD) negative status, suggesting that this therapy may achieve a "limited course of treatment" instead of traditional long-term maintenance therapy.

In addition, this combination regimen also shows superior control capabilities for patients with complex clonal evolution, high-risk TP53 mutations or BTK mutations, indicating that it is expected to break through the bottleneck of traditional treatment and become an important direction for personalized treatment in the future.

3. Safety is generally controllable, but some patients require close monitoring

Although combining the two drugs can improve the efficacy, will it bring more adverse reactions? Judging from existing studies, the safety profile of the combination of venetoclax and pitobrutinib is generally acceptable.

Common adverse reactions of venetoclax include neutropenia, anemia, gastrointestinal reactions, etc.; while the side effects of pitobrutinib are milder, and compared with ibrutinib, it causes significantly fewer problems such as arrhythmia, bleeding, and rash. This provides a safe basis for combined drug use.

In combination regimens, common adverse events still include bone marrow suppression, abnormal liver function and tumor lysis syndrome (TLS). In particular, the risk of venetoclax needs to be strictly managed in the early stages of dose escalation. TLS risks. In addition, some patients may experience mild to moderate side effects such as diarrhea, infection, or fatigue, and most of them can be relieved with supportive treatment.

To ensure patient safety, it is recommended to conduct risk assessment before treatment, including tumor burden assessment, electrolyte level monitoring, etc. In actual treatment, a "stepped regimen" of gradually increasing doses of venetoclax should be adopted, combined with preventive hydration and drugs to prevent TLS. Pitobrutinib can be taken orally once a day at a fixed time without the need for frequent dose adjustments, which increases patient compliance.

4. The future is promising and may reshapeCLLthe treatment landscape

With the release of more clinical trial data, the combination treatment of venetoclax and pitobrutinib is expected to become one of the core strategies for the next generation of CLL treatment. Compared with traditional treatments, it has a higher response rate, deeper molecular response, and the potential to achieve a limited course of treatment or even discontinuation of treatment, bringing patients longer disease-free survival and better quality of life.

Currently, the United StatesFDA has approved pitobrutinib for patients with CLL and SLL who have failed BTK inhibitor treatment, and venetoclax has also been widely recognized for multiple indications. In the future, this combination is expected to undergo more validation in treatment-naïve populations and even become the first-line standard therapy. At the same time, its application scope may also be expanded for other types of BB cell lymphoma, such as mantle cell lymphoma, marginal zone lymphoma, etc.

To sum up, the combination treatment of venetoclax and pitobrutinib provides a more promising treatment option for patients with hematological tumors, especially CLL patients. Its complementary mechanisms of action, high response rate and controllable safety indicate that it will become one of the mainstream treatment strategies in the future. However, clinical application still requires doctors to strictly evaluate the patient's condition, formulate individualized plans, and closely monitor treatment responses and side effects to achieve a balance between maximum efficacy and minimum risk.

Reference materials:https://www.drugs.com/